LEXINGTON, Mass., March 3, 2020 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of agents designed to activate immune response to cancers,
today announced it will release its fourth quarter and
full year 2019 financial results before the market opens
on Thursday, March 12, 2020. Agenus executives will host a
conference call and webcast at 8:30 a.m. ET the same
day.
Conference Call and Webcast Information:
Date: Thursday, March 12, 2020
Time: 8:30 a.m. ET
Domestic Dial-in Number: 1-844-492-3727 (U.S.)
International Dial-in Number: 1-412-317-5118 (International)
Conference ID: Agenus
The call will also be webcast and will be accessible from the
Company's website at
http://investor.agenusbio.com/presentation-webcasts or
via the link:
https://www.webcaster4.com/Webcast/Page/1556/33333.
A replay will be available on the Company's website
approximately two hours after the call.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the
discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and twitter.
Contact:
Agenus Inc.
Regina Grebla, PhD
781-674-4495
Regina.Grebla@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-12-2020-with-conference-call-and-webcast-301014908.html
SOURCE Agenus Inc.